Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

9.78
-0.5100-4.96%
Post-market: 9.920.1400+1.43%19:30 EDT
Volume:1.73M
Turnover:17.11M
Market Cap:852.40M
PE:-4.59
High:10.34
Open:10.29
Low:9.65
Close:10.29
52wk High:36.26
52wk Low:6.65
Shares:87.16M
Float Shares:71.89M
Volume Ratio:1.56
T/O Rate:2.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1289
EPS(LYR):-1.8700
ROE:-52.74%
ROA:-31.82%
PB:1.98
PE(LYR):-5.23

Loading ...

Olema Pharmaceuticals is Maintained at Buy by Stifel

Dow Jones
·
Yesterday

Top Premarket Decliners

MT Newswires Live
·
Sep 14

Goldman Sachs Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Sep 14

Olema selloff on AstraZeneca miss a buying opportunity, says Citi

TIPRANKS
·
Sep 14

Olema Maintained at Buy as Analyst Sees Post-SERENA-4 Pullback as Opportunity, Reiterates $59 Price Target

TIPRANKS
·
Sep 14

Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN) and Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Aug 20

Olema Oncology appoints Jason O’Byrne as CFO

TIPRANKS
·
Aug 17

Olema Pharmaceuticals is Maintained at Overweight by JP Morgan

Dow Jones
·
Aug 13

Olema Pharmaceuticals Names Jason O’Byrne CFO

Reuters
·
Aug 13

Olema Oncology Appoints Jason O’byrne as Chief Financial Officer

THOMSON REUTERS
·
Aug 13

Press Release: Olema Oncology Appoints Jason O'Byrne as Chief Financial Officer

Dow Jones
·
Aug 13

Longeveron Q2 Net Loss Widens on Higher Legal, Clinical Trial Costs

Reuters
·
Aug 13

Sutro Biopharma Q2 Revenue Misses Estimates, Posts Wider Loss

Reuters
·
Aug 12

Oncology Firm Immunome's Q2 Net Loss Widens as R&D Costs Rise

Reuters
·
Aug 12

Sellas Life Sciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 12

Erasca Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 12

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Benzinga Earnings
·
Aug 12

Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Damora Therapeutics (DMRA)

TIPRANKS
·
Aug 11

Imunon Q2 Net Loss Widens Slightly as R&D Costs Rise

Reuters
·
Aug 11

Tyler Van Buren Reiterates Buy on Olema, Citing Palazestrant’s Late-Stage Differentiation and Multiple Value-Creating Catalysts

TIPRANKS
·
Aug 11